ERBELLA, the premium medical aesthetics brand by USCarePharm, announced its successful participation in the 15th Annual Summer Conference of the Korean Academy of Aesthetic and Anti-Aging Dermatology (KAAD), held on August 10 at Seoul Dragon City Hotel. KAAD is a highly respected academic society comprised of board-certified dermatologists in Korea, setting authoritative guidelines for anti-aging treatments including botulinum toxin and filler procedures. This year’s summer conference featured a comprehensive program covering basic science, advanced techniques, clinical applications, and emerging practices, designed to enhance the expertise of participating physicians. Showcasing ERBELLA’s Skin Booster Line At the event, ERBELLA unveiled its innovative liquid PLLA skin booster, ERBELLA PLA Plus AQ, alongside a lineup of boosters tailored to diverse skin concerns. The booth drew strong interest with engaging activities such as product preference surveys, brand quizzes, and prize events, further amplifying audience engagement. Over 200 dermatologists participated in the product survey, demonstrating significant interest in ERBELLA’s portfolio. Among the highlights were: ERBELLA NMN – improves skin texture with NMN-based anti-aging benefits Melathion – a brightening solution for pigmentation care Anti-AC PTT – acne solution leveraging patented Theramogen AT for anti-inflammatory efficacy ExoRN – a regenerative booster combining exosomes and PDRN Spotlight on ERBELLA PLA Plus AQ The most inquired-about product of the day was ERBELLA PLA Plus AQ, the world’s first commercialized liquid PLLA skin booster. Developed using USCarePharm’s patented technology, this product eliminates the need for a separate reconstitution process and features uniformly porous PLLA particles. These properties enhance cell adhesion, improve skin texture, and provide lasting hydration, positioning ERBELLA PLA Plus AQ as a breakthrough in skin rejuvenation. Advancing K-Anti-Aging Solutions “Through this conference, we were able to share the latest developments in anti-aging research with Korean dermatologists and exchange valuable clinical insights,” said an ERBELLA representative. “Moving forward, ERBELLA will continue to provide trusted K-Anti-Aging solutions and pioneer a new paradigm in aesthetic medicine.” Expanding Global Footprint Following the KAAD conference, ERBELLA is set to participate in InterCHARM Russia and Beautyworld Middle East (Dubai) this October. With continuous product innovation and global marketing initiatives, the brand aims to strengthen its position as a leading player in the international medical aesthetics market.

2025.08.22 16:20

USCarePharm Co., Ltd., a leader in natural material-based R&D, announced its recent presentation of new research on vascular health functional ingredients at the Annual Conference of the Korean Society of Pharmacognosy. During the academic forum, USCarePharm unveiled the results of its advanced research into plant-derived bioactive compounds that demonstrated efficacy in supporting vascular wall integrity and circulatory health. The study focused on a newly identified material, USCP0112, which showed promise in improving endothelial function, reducing oxidative stress, and modulating lipid metabolism — all crucial factors in vascular wellness. This achievement is part of USCarePharm’s broader UMAP Tech™ platform, which specializes in the systematic discovery, screening, and optimization of high-performance natural ingredients for use in pharmaceuticals, functional foods, and cosmeceuticals. “The results we shared reflect years of targeted research in functional ingredients derived from traditional medicinal plants,” said CEO Song Seok-jin. “We are committed to transforming these findings into clinically meaningful applications that promote cardiovascular wellness and overall health.” The presentation further strengthens USCarePharm’s reputation as a pioneer in bio-convergent healthcare innovation, capable of bridging the gap between traditional natural remedies and scientifically validated modern therapeutics. USCarePharm plans to continue collaboration with academic institutions and industry partners to accelerate the commercialization of science-based natural health solutions.

2025.07.28 14:10

USCarePharm Co., Ltd., a leading innovator in bio-based functional ingredients, will unveil its latest research on vascular anti-aging and health-supporting materials at the 53rd Annual General Meeting & Scientific Conference of the Korean Society of Pharmacognosy, to be held on November 3–4 at Ewha Womans University ECC. The company will present preclinical study results on USCP-GHV-014, a proprietary natural material demonstrating significant efficacy in reducing intimal-medial thickness (IMT) and inhibiting collagen deposition in blood vessels. The findings suggest preserved vascular elasticity and reduced pulse pressure, both crucial indicators for cardiovascular health. As vascular aging begins as early as in the 20s, structural stiffening of arterial walls and loss of elasticity increase pulse pressure — the difference between systolic and diastolic blood pressure. This pressure widening is a strong predictor of cardiovascular risk. Given the rise in vascular-related concerns among younger populations due to high-fat diets, sedentary lifestyles, and chronic stress, proactive vascular care has become essential across all age groups. “We are proud to present the promising preclinical data of USCP-GHV-014 in preventing vascular aging at this prestigious conference,” said CEO Song Seok-jin of USCarePharm. “Following successful human application trials, we aim to open a new frontier in the vascular wellness market with scientifically validated and systematically developed natural health ingredients.” USCP-GHV-014 is being developed under the High Value-Added Food Technology Development Program, supported by the Korea Institute of Planning and Evaluation for Technology in Food, Agriculture, and Forestry (IPET). The company is also pursuing intellectual property rights to protect its novel formulation.

2025.07.28 14:09